Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Guggenheim analyst Brad Canino assumes Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $15.
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price targ...
Raymond James analyst Dane Leone maintains Relay Therapeutics (NASDAQ:RLAY) with a Strong Buy and lowers the price target fr...
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(...
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3...
Guggenheim analyst Michael Schmidt maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $3...
